Please check your internet connection and try again.
# Tabgenixim (Cefixime)
## Overview
Tabgenixim is a brand-name formulation of **Cefixime**, a third-generation oral cephalosporin. It functions by inhibiting bacterial cell wall synthesis via binding to penicillin-binding proteins (PBPs). It displays high stability against many beta-lactamases produced by Gram-negative organisms.
## Primary Indications
* Uncomplicated urinary tract infections (UTIs)
* Otitis media
* Pharyngitis and tonsillitis
* Gonococcal infections (uncomplicated)
* Acute bronchitis/exacerbations of chronic bronchitis
## Adult Dosing
* **Respiratory/UTI:** 400 mg daily, administered as a single dose or in two divided doses (200 mg every 12 hours).
* **Uncomplicated Gonorrhea:** 400–800 mg as a single oral dose (Note: IDSA/CDC guidelines prefer intramuscular ceftriaxone; verify local susceptibility and current guidelines).
## Pediatric Dosing
* **General Infections (≥6 months):** 8 mg/kg/day, administered as a single dose or in two divided doses (4 mg/kg every 12 hours).
* **Maximum Dose:** 400 mg/day.
## Dose Adjustments
* **Renal Impairment:** If CrCl 21–60 mL/min, reduce dose to 75% of the standard dose. If CrCl <20 mL/min, reduce dose to 50% of the standard dose.
* **Hemodialysis:** No supplemental dose required; clearance by dialysis is minimal.
## Contraindications
* Known hypersensitivity to cefixime or other cephalosporins.
* History of severe allergic reactions (e.g., anaphylaxis) to penicillins or other beta-lactams.
## Adverse Effects
* **Common:** Diarrhea (frequently dose-dependent), abdominal pain, nausea, dyspepsia, flatulence.
* **Serious:** *Clostridioides difficile*-associated diarrhea, hypersensitivity reactions (rash, urticaria, serum sickness), and rare cases of Stevens-Johnson syndrome or toxic epidermal necrolysis.
## Key Drug Interactions
* **Warfarin:** Cefixime may enhance the anticoagulant effect; monitor INR closely.
* **Aminoglycosides:** Potential for increased nephrotoxicity (though less common than with parenteral cephalosporins).
* **Probenecid:** May increase serum concentrations of cefixime by inhibiting renal excretion.
## Monitoring
* Monitor for signs of anaphylaxis during the first dose.
* In patients with prolonged therapy, monitor renal and hepatic function, and watch for signs of secondary superinfection (e.g., candidiasis, *C. difficile*).
## Clinical Pearls
* **Absorption:** Oral absorption is not significantly affected by food.
* **Spectrum:** While it covers many Gram-negative rods (e.g., *E. coli, Proteus, Klebsiella*), it has **poor activity** against *Staphylococcus aureus* and *Enterococcus* species.
* **Formulation:** Ensure the correct concentration is prescribed for pediatric suspensions to avoid dosing errors.
* **Local Variability:** Resistance patterns vary significantly by region; always consult local antibiograms before initiation for empiric therapy.
***
**Disclaimer:** This information is clinical support for healthcare professionals. Dosing and therapeutic protocols may vary by institution and patient-specific factors. Always verify current prescribing information, local susceptibility data, and treatment guidelines (e.g., CDC/IDSA) before clinical use.
